iX Biopharma (SGX:42C) said warrant holders have exercised about 92% of the warrants issued under its 2024 rights issue by July 15, converting them into roughly 53 million new shares, according to a Thursday Singapore Exchange filing.
Management and directors accounted for around 24.2 million shares, or 46% of all warrants exercised, reflecting strong insider confidence.
The warrant exercises raised most of the potential SG$3.5 million in proceeds, which iX Biopharma said will support its balance sheet and U.S. expansion through the compounding pharmacy pathway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.